Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has accepted a BLA from UCB for Cimzia (certolizumab pegol) seeking an indication for rheumatoid arthritis, the Brussels, Belgium-based biotech announced Feb. 6. The filing, for monotherapy or treatment in combination with methotrexate, is slated for a standard review, giving the application an early December action date

You may also be interested in...



UCB To Provide More Cimzia Information Following FDA "Complete Response"

UCB will have to submit "additional information" and clarifications to FDA following receipt of a "complete response" letter from the agency for its PEGylated Fab fragment TNF inhibitor Cimzia (certolizumab pegol) for treatment of Crohn's disease, the company said Dec. 22

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.

Topics

UsernamePublicRestriction

Register

PS003779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel